ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Carb-X, a public-private partnership, will award the Helmholtz Center for Infection Research up to $15 million to develop two small-molecule antibiotics. One compound is an inhibitor of α-hemolysin, a toxin employed by Staphylococcus aureus that damages lung tissue and immune cells. The second is an inhibitor of elastase B, a metalloenzyme used by Pseudomonas aeruginosa during infections. Both approaches rely on blunting damage from infections rather than killing the bacteria directly, which could help stall antibiotic resistance.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X